Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2026-03-04 @ 3:44 PM
Study NCT ID:
NCT04201418
Status:
COMPLETED
Last Update Posted:
2022-06-06
First Post:
2019-12-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000686', 'term': 'Amyloidosis'}, {'id': 'D011115', 'term': 'Polyneuropathies'}, {'id': 'D028227', 'term': 'Amyloid Neuropathies, Familial'}, {'id': 'C567782', 'term': 'Amyloidosis, Hereditary, Transthyretin-Related'}, {'id': 'D017772', 'term': 'Amyloid Neuropathies'}, {'id': 'D028226', 'term': 'Amyloidosis, Familial'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}], 'ancestors': [{'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000606954', 'term': 'patisiran'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 67}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-12-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-06', 'completionDateStruct': {'date': '2022-05-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-03', 'studyFirstSubmitDate': '2019-12-13', 'studyFirstSubmitQcDate': '2019-12-13', 'lastUpdatePostDateStruct': {'date': '2022-06-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-12-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-24', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants with Stable or Improved Polyneuropathy Disability (PND) Score at 12 Months Relative to Baseline', 'timeFrame': 'Baseline, Month 12', 'description': 'PND Scores: Stage 0=No symptoms, Stage 1=Sensory disturbances but preserved walking capability, Stage 2=Impaired walking capacity, but ability to walk without a stick or crutches, Stage 3A/B=Walking with the help of 1 or 2 sticks or crutches, Stage 4=confined to wheel chair or bedridden.'}]}, 'oversightModule': {'isUsExport': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Valine to isoleucine substitution at position 122', 'V122I', 'Threonine to alanine substitution at position 60', 'T60A', 'Familial Amyloid Polyneuropathies', 'ATTR', 'Transthyretin amyloidosis', 'Transthyretin', 'Amyloidosis', 'TTR-mediated Amyloidosis', 'RNAi therapeutic', 'FAP', 'Polyneuropathies', 'Amyloid neuropathies', 'Amyloid neuropathies, familial', 'Amyloidosis, familial', 'Peripheral nervous system diseases', 'Nervous system diseases', 'TTR', 'Neuromuscular diseases', 'Proteostasis deficiencies', 'Metabolic diseases', 'Heredodegenerative disorders, nervous system', 'Neurodegenerative diseases', 'Genetic diseases, inborn', 'Metabolism, inborn errors', 'ATTRv'], 'conditions': ['Hereditary Transthyretin-mediated (ATTRv) Amyloidosis', 'Polyneuropathy']}, 'descriptionModule': {'briefSummary': 'To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Participants with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A mutation\n* PND score of I-IIIB at baseline.\n* Exposure to commercial patisiran in one of the 3 cohorts:\n\n * Prospective Cohort: Naive to patisiran treatment at the time of enrollment with intention to initiate treatment with patisiran.\n * Mixed cohort: Currently on commercial patisiran therapy for less than 12 months at study enrollment.\n * Retrospective cohort: Exposed to commercial patisiran treatment for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) heart failure classification ≥3\n* Karnofsky Performance Status (KPS) \\<60%\n* Unstable congestive heart failure (CHF)\n* Known primary amyloidosis (AL) or leptomeningeal amyloidosis\n* Prior major organ transplant\n* Previously received patisiran\n* Previous treatment with a TTR silencing therapy'}, 'identificationModule': {'nctId': 'NCT04201418', 'briefTitle': 'A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation', 'organization': {'class': 'INDUSTRY', 'fullName': 'Alnylam Pharmaceuticals'}, 'officialTitle': 'A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation', 'orgStudyIdInfo': {'id': 'ALN-TTR02-012'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patisiran Prospective Cohort', 'description': 'Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.', 'interventionNames': ['Drug: Patisiran']}, {'label': 'Patisiran Mixed Cohort', 'description': 'Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.', 'interventionNames': ['Drug: Patisiran']}, {'label': 'Patisiran Retrospective Cohort', 'description': 'Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.', 'interventionNames': ['Drug: Patisiran']}], 'interventions': [{'name': 'Patisiran', 'type': 'DRUG', 'otherNames': ['ONPATTRO', 'ALN-TTR02'], 'description': 'Patisiran-lipid complex injection, for intravenous use', 'armGroupLabels': ['Patisiran Mixed Cohort', 'Patisiran Prospective Cohort', 'Patisiran Retrospective Cohort']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92103', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '06030', 'city': 'Farmington', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 41.71982, 'lon': -72.83204}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33609', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30517', 'city': 'Braselton', 'state': 'Georgia', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 34.10927, 'lon': -83.76267}}, {'zip': '31201', 'city': 'Macon', 'state': 'Georgia', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 32.84069, 'lon': -83.6324}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '39216', 'city': 'Jackson', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 32.29876, 'lon': -90.18481}}, {'zip': '64111', 'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'zip': '68198', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '27599', 'city': 'Chapel Hill', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '28207', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '18103', 'city': 'Allentown', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 40.60843, 'lon': -75.49018}}, {'zip': '18015', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'zip': '17602', 'city': 'Lancaster', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 40.03788, 'lon': -76.30551}}, {'zip': '15212', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '38138', 'city': 'Germantown', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}}, {'zip': '78756', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Clinical Trial Site', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Alnylam Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Alnylam Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}